Company intelligence / Profile preview
ZENOAQ
- Ownership
- Private
- Employees
- ~600
- Development stage
- Other
Overview
ZENOAQ has a long history of developing and commercializing both veterinary and human pharmaceuticals. It was the first to launch a desensitization therapy for house dust mite-induced canine atopic dermatitis. In the human sector, it co-markets Rituxan (rituximab) with Chugai Pharmaceutical in Japan for multiple oncology and autoimmune indications. The company also has ongoing research interests in dermatology, cancer, autoimmune diseases, and antibody therapeutics.
- Therapeutic areas
- DermatologyImmunologyOncologyInfectious Diseases
- Modalities
- Small moleculeBiologicMonoclonal antibodyRecombinant protein
- Industry
- Veterinary
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on ZENOAQ.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZENOAQ.